Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases

Expert Review of Vaccines

Volumn 10, Issue 11, 2011, Pages 1539-1552

  Zhang, Jianfeng ^a   Tarbet, E Bart ^b   Toro, Haroldo ^c   Tang, De Chu C ^a  

^a Vaxin Incorporated   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

adenovirus; drug resistance; drug vaccine duo; influenza therapy; mass immunization; nasal vaccine; safety; vaccine

Indexed keywords

ADENOVIRUS SEROTYPE 5 VECTORED INFLUENZA DRUG VACCINE DUO; ADENOVIRUS VECTOR; AMANTADINE; ANGOLA MARBURG VIRUS GLYCOPROTEIN; ANTHRAX VACCINE; APICAL MEMBRANE ANTIGEN 1; AVIAN INFLUENZA VACCINE; BACTERIAL TOXIN; BCG VACCINE; BOTULINUM TOXIN; CIRCUMSPOROZOITE PROTEIN; EBOLA VACCINE; GAG PROTEIN; HANTAVIRUS NUCLEOCAPSID; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; MEASLES VACCINE; NEF PROTEIN; ORAL POLIOMYELITIS VACCINE; ORNITHINE CARBAMOYLTRANSFERASE; OSELTAMIVIR; POL PROTEIN; RABIES VACCINE; RIMANTADINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; V ANTIGEN; VIRUS ANTIGEN; VIRUS VACCINE; ZANAMIVIR;

ADENOVIRUS 5; ANTHRAX; ANTIGEN PRESENTING CELL; AVIAN INFLUENZA; BELL PALSY; BOTULISM; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG STORAGE; EBOLA HEMORRHAGIC FEVER; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; HANTAVIRUS INFECTION; HERD IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS; MALARIA; MASS IMMUNIZATION; MEASLES; MUCOSAL IMMUNITY; NON INVASIVE PROCEDURE; NONHUMAN; ORNITHINE TRANSCARBAMYLASE DEFICIENCY; PERICARDITIS; POLIOMYELITIS; PRIORITY JOURNAL; RABIES; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SWINE INFLUENZA; TRANSGENE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS PARTICLE; YERSINIA INFECTION;

ADENOVIRUSES, HUMAN; ADMINISTRATION, INTRANASAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; VACCINATION; VACCINES;

EID: 80455174421     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.141     Document Type: Review

References (117)

1. Salomon ME, Halperin R, Yee J. Evaluation of the two-needle strategy for reducing reactions to DPT vaccination. Am. J. Dis. Child. 141, 796-798 (1987). (Pubitemid 17089375)
2. Lanza GA, Barone L, Scalone G et al. Inflammation-related effects of adjuvant influenza A vaccination on platelet activation and cardiac autonomic function. J. Intern. Med. 269, 118-125 (2011).
3. Jae SY, Heffernan KS, Park SH et al. Does an acute inflammatory response temporarily attenuate parasympathetic reactivation? Clin. Auton. Res. 20, 229-233 (2010).
4. Sever JL, Brenner AI, Gale AD et al. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol. Drug Saf. 13, 825-840 (2004). (Pubitemid 40003818)
5. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 27, 2649-2652 (2009).
6. Poland GA, Grabenstein JD, Neff JM. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 23, 2078-2081 (2005). (Pubitemid 40341430)
7. Lewis DJ, Huo Z, Barnett S et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4, e6999 (2009).
8. Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N. Engl. J. Med. 350, 860-861 (2004). (Pubitemid 38252532)
9. Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am. J. Pathol. 156, 2057-2065 (2000). (Pubitemid 30641773)
10. Finch CE, Crimmins EM. Inflammatory exposure and historical changes in human life-spans. Science 305, 1736-1739 (2004). (Pubitemid 39249633)
11. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415-445 (2011).
12. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J. Thorac. Oncol. 5, 2024-2036 (2010).
13. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10, 411-418 (2010).
14. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J. Exp. Med. 184, 1879-1890 (1996). (Pubitemid 26404478)
15. Saurer L, McCullough KC, Summerfield A. In vitro induction of mucosa-type dendritic cells by all-trans retinoic acid. J. Immunol. 179, 3504-3514 (2007).
16. Molenaar R, Greuter M, van der Marel AP et al. Lymph node stromal cells support dendritic cell-induced gut-homing of T cells. J. Immunol. 183, 6395-6402 (2009).
17. Tang DC, Van Kampen KR. Toward the development of vectored vaccines in compliance with evolutionary medicine. Expert Rev. Vaccines 7(4), 399-402 (2008). (Pubitemid 351656810)
18. Karron RA, Talaat K, Luke C et al. Evaluation of two live attenuated coldadapted H5N1 influenza virus vaccines in healthy adults. Vaccine 27, 4953-4960 (2009).
19. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirusvectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23, 1029-1036 (2005). (Pubitemid 40037652)
20. Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature 388, 729-730 (1997).
21. Zhang J, Shi Z, Kong FK et al. Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity. Infect. Immun. 74, 3607-3617 (2006). (Pubitemid 43794552)
22. Glenn GM, Taylor DN, Li X et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6, 1403-1406 (2000). (Pubitemid 32001027)
23. Sullivan SP, Koutsonanos DG, del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16, 915-920 (2010).
24. Kaplan DH. In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol. 31, 446-451 (2010).
25. Soloff AC, Barratt-Boyes SM. Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell Res. 20, 872-885 (2010).
26. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. Science 309, 264-268 (2005). (Pubitemid 40967855)
27. Feng T, Cong Y, Qin H, Benveniste EN, Elson CO. Generation of mucosal dendritic cells from bone marrow reveals a critical role of retinoic acid. J. Immunol. 185, 5915-5925 (2010).
28. + T lymphocytes. J. Virol. 84, 5986-5996 (2010).
29. San Martín C, Burnett RM. Structural studies on adenoviruses. Curr. Top. Microbiol. Immunol. 272, 57-94 (2003). (Pubitemid 36458325)
30. Lichtenstein DL, Wold WS. Experimental infections of humans with wild-type adenoviruses and with replicationcompetent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 11, 819-829 (2004). (Pubitemid 39636349)
31. Howell MR, Nang RN, Gaydos CA, Gaydos JC. Prevention of adenoviral acute respiratory disease in Army recruits: cost- effectiveness of a military vaccination policy. Am. J. Prev. Med. 14, 168-175 (1998). (Pubitemid 28173268)
32. Haj-Ahmad Y, Graham FL. Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene. J. Virol. 57, 267-274 (1986). (Pubitemid 16147942)
33. Zhu J, Grace M, Casale J et al. Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector. Hum. Gene Ther. 10, 113-121 (1999). (Pubitemid 29046151)
34. Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917 (1998). (Pubitemid 28439096)
35. Tang DC, Zhang J, Toro H, Shi Z, Van Kampen KR. Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. Expert Rev. Vaccines 8, 469-481 (2009).
36. Wang L, Cheng C, Ko SY et al. Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J. Virol. 83, 7166-7175 (2009).
37. Tang J, Olive M, Champagne K et al. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele. Gene Ther. 11, 1408-1415 (2004). (Pubitemid 39263894)
38. Nwanegbo E, Vardas E, Gao W et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11, 351-357 (2004). (Pubitemid 38380817)
39. Barouch DH, Kik SV, Weverling GJ et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29, 5203-5209 (2011).
40. Yang Y, Nunes FA, Berencsi K et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl Acad. Sci. USA 91, 4407-4411 (1994). (Pubitemid 24143442)
41. Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3, e3548 (2008).
42. Stone D, Liu Y, Li ZY et al. Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol. Ther. 15, 2146-2153 (2007). (Pubitemid 350148931)
43. Sharma A, Bangari DS, Tandon M et al. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386, 44-54 (2009).
44. Roy S, Medina-Jaszek A, Wilson MJ et al. Creation of a panel of vectors based on ape adenovirus isolates. J. Gene Med. 13, 17-25 (2011).
45. Patel A, Tikoo S, Kobinger G. A porcine adenovirus with low human seroprevalence is a promising alternative vaccine vector to human adenovirus 5 in an H5N1 virus disease model. PLoS ONE 5, e15301 (2010).
46. Chen EC, Yagi S, Kelly KR et al. Crossspecies transmission of a novel adenovirus associated with a fulminant pneumonia outbreak in a new world monkey colony. PLoS Pathog. 7, e1002155 (2011).
47. Seto J, Walsh MP, Metzgar D, Seto D. Computational analysis of adenovirus serotype 5 (HAdV-C5) from an HAdV coinfection shows genome stability after 45 years of circulation. Virology 404, 180-186 (2010).
48. Boyer JL, Sofer-Podesta C, Ang J et al. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum. Gene Ther. 21, 891-901 (2010).
49. Worgall S, Krause A, Qiu J et al. Protective immunity to Pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J. Virol. 81, 13801-13808 (2007). (Pubitemid 350247873)
50. Osada T, Yang XY, Hartman ZC et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther. 16, 673-682 (2009).
51. Gabitzsch ES, Xu Y, Yoshida LH et al. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27, 6394-6398 (2009).
52. Parks RJ, Chen L, Anton M et al. A helperdependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl Acad. Sci. USA 93, 13565-13570 1996). (Pubitemid 26424159)
53. Shi Z, Zeng M, Yang G et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J. Virol. 75, 11474-11482 (2001). (Pubitemid 33063239)
54. Song K, Bolton DL, Wilson RL et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proc. Natl Acad. Sci. USA 107, 22213-22218 (2010).
55. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158 (2003). (Pubitemid 37272241)
56. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132, 1-14 (2008). (Pubitemid 351232078)
57. Higashimoto Y, Yamagata Y, Itoh H. Complex effect of adenovirus early region proteins on innate immune system. Inflamm. Allergy Drug Targets 5, 229-237 (2006). (Pubitemid 44941933)
58. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
59. McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case- cohort analysis. Lancet 372, 1894-1905 (2008).
60. Appledorn DM, Aldhamen YA, Godbehere S, Seregin SS, Amalfitano A. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity. Clin. Vaccine Immunol. 18, 150-160 (2011).
61. Benlahrech A, Harris J, Meiser A et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with amucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl Acad. Sci. USA 106, 19940-19945 (2009).
62. Joseph A, Itskovitz-Cooper N, Samira S et al. A new intranasal influenza vaccine based on a novel polycationic lipid - ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24, 3990-4006 (2006).
63. Wang J, Thorson L, Stokes RW et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357-6365 (2004). (Pubitemid 39487795)
64. Ockenhouse C. Prime boost regimens of DNA and adenovirus-vectored malaria vaccines: lessons learned from preclinical and clinical studies. Presented at: Conference of Gene Based Vaccines. Vienna, Austria, 13-14 September 2010.
65. McWilliam AS, Nelson DJ, Holt PG. The biology of airway dendritic cells. Immunol. Cell Biol. 73, 405-413 (1995).
66. Brandtzaeg P. Potential of nasopharynxassociated lymphoid tissue for vaccine responses in the airways. Am. J. Respir. Crit. Care Med. 183, 1595-1604 (2011).
67. Lubeck MD, Natuk RJ, Chengalvala M et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res. Hum. Retroviruses 10, 1443-1449 (1994). (Pubitemid 24382196)
68. Lemiale F, Kong WP, Akyurek LM et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77, 10078-10087 (2003). (Pubitemid 37122089)
69. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177, 1155-1161 (1998). (Pubitemid 28194251)
70. Lobanova LM, Baig TT, Tikoo SK, Zakhartchouk AN. Mucosal adenovirusvectored vaccine for measles. Vaccine 28, 7613-7619 (2010).
71. + dendritic cells. Immunol. Rev. 234, 268-281 (2010).
72. Zhang Z, Krimmel J, Zhang Z, Hu Z, Seth P. Systemic delivery of a novel liverdetargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum. Gene Ther. (In Press) (2011).
73. Li C, Ziegler RJ, Cherry M et al. Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease. Mol. Ther. 5, 745-754 (2002). (Pubitemid 34619067)
74. Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med. Infect. Dis. 6, 114-124 (2008).
75. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 71, 1591-1622 (2011).
76. Zhang SY, Jouanguy E, Ugolini S et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317, 1522-1527 (2007). (Pubitemid 47417427)
77. Hoelscher MA, Garg S, Bangari DS et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481 (2006). (Pubitemid 43208903)
78. Gao W, Soloff AC, Lu X et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J. Virol. 80, 1959-1964 (2006). (Pubitemid 43228735)
79. Xiang ZQ, Yang Y, Wilson JM, Ertl HC. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219, 220-227 (1996). (Pubitemid 26180398)
80. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152-154 (1992).
81. Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled Phase 1b clinical trial. Vaccine 27, 2506-2512 (2009).
82. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1748 (1993).
83. van Drunen Littel-van den Hurk S, Hannaman D. Electroporation for DNA immunization: clinical application. Expert Rev. Vaccines 9(5), 503-517 (2010).
84. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat. Rev. Genet. 9, 776-788 (2008).
85. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16, 1016-1027 (2005). (Pubitemid 41324561)
86. Evans RK, Nawrocki DK, Isopi LA et al. Development of stable liquid formulations for adenovirus-based vaccines. J. Pharm. Sci. 93, 2458-2475 (2004). (Pubitemid 39319430)
87. Alcock R, Cottingham MG, Rollier CS et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci. Transl. Med. 2, 19ra12 (2010).
88. Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther. 8, 1281-1290 (2001). (Pubitemid 32834296)
89. Zhang J, Tarbet EB, Feng T et al. Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza. PLoS ONE 6, e22605 (2011).
90. Yamaguchi T, Kawabata K, Kouyama E et al. Induction of type I interferon by adenovirus-encoded small RNAs. Proc. Natl Acad. Sci. USA 107, 17286-17291 (2010).
91. Thiele AT, Sumpter TL, Walker JA et al. Pulmonary immunity to viral infection: adenovirus infection of lung dendritic cells renders T cells nonresponsive to interleukin-2. J. Virol. 80, 1826-1836 (2006). (Pubitemid 43228723)
92. Zhu J, Huang X, Yang Y. A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16, 1300-1307 (2008). (Pubitemid 351866062)
93. Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS ONE 4, e4176 (2009).
94. Norton EB, Clements JD, Voss TG, Cárdenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J. Virol. 84, 2983-2995 (2010).
95. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin. Infect. Dis. 48, 1254-1256 (2009).
96. Takahashi E, Kataoka K, Fujii K et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect. 12, 778-783 (2010).
97. Toro H, Tang DC, Suarez DL et al. Protective avian influenza in ovovaccination with non-replicating human adenovirus vector. Vaccine 25, 2886-2891 (2007). (Pubitemid 46412564)
98. Toro H, Tang DC, Suarez DL, Zhang J, Shi Z. Protection of chickens against avian influenza with non-replicating adenovirusvectored vaccine. Vaccine 26, 2640-2646 (2008).
99. Toro H, Tang DC. Protection of chickens against avian influenza with nonreplicating adenovirus-vectored vaccine. Poult. Sci. 88, 867-871 (2009).
100. Avakian AP, Poston RM, Kong FK, Van Kampen KR, Tang DC. Automated mass immunization of poultry: the prospect for nonreplicating human adenovirus-vectored in ovo vaccines. Expert Rev. Vaccines 6(3), 457-465 (2007). (Pubitemid 46911607)
101. + T lymphocytes. Virology 405, 62-69 (2010).
102. Toro H, Suarez DL, Tang DC, van Ginkel FW, Breedlovea C. Avian influenza mucosal vaccination in chickens with replication-defective recombinant adenovirus vaccine. Avian Dis. 55, 43-47 (2011).
103. van Ginkel F, Tang DC, Gulley SL, Toro H. Induction of mucosal immunity in the avian Harderian gland with a replicationdeficient Ad5 vector expressing avian influenza H5 hemagglutinin. Dev. Comp. Immunol. 33, 28-34 (2009).
104. Wesley RD, Tang M, Lager KM. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22, 3427-3434 (2004). (Pubitemid 39078761)
105. Toro H, van Ginkel FW, Tang DC et al. Avian influenza vaccination in chickens and pigs with replication-competent adenovirus-free human recombinant adenovirus 5. Avian Dis. 54(1 Suppl.), 224-231 (2010).
106. Henderson H, Jackson F, Bean K et al. Oral immunization of raccoons and skunks with a canine adenovirus recombinant rabies vaccine. Vaccine 27, 7194-7197 (2009).
107. Geisbert TW, Bailey M, Hensley L et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85, 4222-4233 (2011).
108. Pratt WD, Wang D, Nichols DK et al. Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin. Vaccine Immunol. 17, 572-581 (2010).
109. Geisbert TW, Bailey M, Geisbert JB et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84, 10386-10394 (2010).
110. Xing Z, McFarland CT, Sallenave JM et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS ONE 4, e5856 (2009).
111. McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol. Ther. 15, 203-210 2007). (Pubitemid 46043666)
112. Wei CJ, Boyington JC, McTamney PM et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064 (2010).
113. Safronetz D, Hegde NR, Ebihara H et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus. J. Virol. 83, 7285-7295 (2009).
114. Xu Q, Pichichero ME, Simpson LL et al. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther. 16, 367-375 (2009).
115. Chiuchiolo MJ, Boyer JL, Krause A et al. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J. Infect. Dis. 194, 1249-1257 (2006). (Pubitemid 44630970)
116. Fox JL. FDA, producers moving toward mammalian cell-based flu vaccines. Microbe 1, 54-55 (2006).
117. Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum. Gene Ther. 16, 157-168 (2005). (Pubitemid 40344208)